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A B S T R A C T
Mechanisms leading to age-related reductions in bone formation and subsequent osteoporosis are still in-
completely understood. We recently demonstrated that kynurenine (KYN), a tryptophan metabolite, accumulates
in serum of aged mice and induces bone loss. Here, we report on novel mechanisms underlying KYN's detri-
mental effect on bone aging.
We show that KYN is increased with aging in murine bone marrow mesenchymal stem cells (BMSCs). KYN
reduces bone formation via modulating levels of CXCL12 and its receptors as well as histone deacetylase 3
(Hdac3). BMSCs responded to KYN by significantly decreasing mRNA expression levels of CXCL12 and its
cognate receptors, CXCR4 and ACKR3, as well as downregulating osteogenic gene RUNX2 expression, resulting
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in a significant inhibition in BMSCs osteogenic differentiation. KYN's effects on these targets occur by increasing
regulatory miRNAs that target osteogenesis, specifically miR29b-1-5p.
Thus, KYN significantly upregulated the anti-osteogenic miRNA miR29b-1-5p in BMSCs, mimicking the up-
regulation of miR-29b-1-5p in human and murine BMSCs with age. Direct inhibition of miR29b-1-5p by an-
tagomirs rescued CXCL12 protein levels downregulated by KYN, while a miR29b-1-5p mimic further decreased
CXCL12 levels. KYN also significantly downregulated mRNA levels of Hdac3, a target of miR-29b-1-5p, as well as
its cofactor NCoR1. KYN is a ligand for the aryl hydrocarbon receptor (AhR). We hypothesized that AhR mediates
KYN's effects in BMSCs. Indeed, AhR inhibitors (CH-223191 and 3′,4′-dimethoxyflavone [DMF]) partially res-
cued secreted CXCL12 protein levels in BMSCs treated with KYN. Importantly, we found that treatment with
CXCL12, or transfection with an miR29b-1-5p antagomir, downregulated the AhR mRNA level, while trans-
fection with miR29b-1-5p mimic significantly upregulated its level. Further, CXCL12 treatment downregulated
IDO, an enzyme responsible for generating KYN. Our findings reveal novel molecular pathways involved in
KYN's age-associated effects in the bone microenvironment that may be useful translational targets for treating
osteoporosis.
1. Introduction
Aging is accompanied by a universal, gradual decline in the in-
tegrity and functionality of organs and tissues. While every organism,
organ, tissue, or cell population is affected by aging differently, the
outcome is universally accompanied by a deterioration in well-being
(López-Otín et al., 2013). The skeletal system, which is an active, re-
sponsive and dynamic tissue, is no exception (Lee et al., 2017). In fact,
aging is the major risk factor for osteoporosis development (Infante and
Rodriguez, 2018; Coipeau et al., 2009). The specific mechanisms un-
derlying age-related bone loss remain incompletely defined, but are
crucial to understand. Bone is a heterogeneous tissue made up of ex-
tracellular matrix (ECM) and different cell populations including me-
senchymal stem cells (MSCs), pre-osteoblasts, osteoblasts, osteocytes,
bone lining cells, osteoclasts, a complex vasculature system, and the
hematopoietic system (Schönherr and Hausser, 2000; Manolagas, 2000;
Manolagas and Parfitt, 2010; Schaffler et al., 2013; Matic et al., 2016;
Kim et al., 2017). MSCs make up a small percentage of bone cells, but
play a vital role in bone modeling and remodeling, fracture repair, and
bone aging (da Silva Meirelles, 2006; Granero-Moltó et al., 2009). The
balance between osteogenic and adipogenic MSC differentiation in
bone marrow is tightly regulated and imperative for bone health
(Coipeau et al., 2009; Stenderup, 2003; Tzeng et al., 2018). The lit-
erature reports a skewed differentiation pattern of bone marrow me-
senchymal stem cells (BMSCs) with age, with both an overall decline in
numbers and a shifting from osteogenic to more adipogenic differ-
entiation (Lefterova et al., 2008; Kim and Ko, 2014; Chen et al., 2016).
According to Infante et al. (Infante and Rodriguez, 2018), this shift from
osteogenesis to adipogenesis in the aging bone marrow MSC population
is orchestrated by a number of factors including transcription factors,
miRNAs, autophagy levels, cell-extrinsic factors, and epigenetic mod-
ifications of DNA.
One such factor of interest is kynurenine (KYN), a primary active
metabolite of tryptophan (TRP) that is produced by ROS-mediated
oxidation and the action of indoleamine 2,3 dioxygenase-1 or -2 (IDO1
or IDO2) (Metz et al., 2014; Reyes Ocampo et al., 2014; Brooks et al.,
2016; Lob et al., 2009; Merlo and Mandik-Nayak, 2016). A high KYN/
TRP ratio is correlated with low bone mineral density (BMD) (Apalset
et al., 2014). The essential amino acid TRP is crucial for anabolic
BMSCs pathways, including those supporting cell proliferation and
differentiation, but KYN inhibits these pathways (El Refaey et al.,
2015). KYN is thought to mainly act through the aryl hydrocarbon re-
ceptor (AhR) (Mezrich et al., 2010; Kurz et al., 2011). Once activated,
cytoplasmic AhR is transported into the nucleus where it binds the aryl
hydrocarbon receptor nuclear translocator (ARNT) and acts as a tran-
scription factor for a wide array of genes (Murray et al., 2014; Beischlag
et al., 2008). We recently tested the hypothesis that a high KYN/TRP
ratio mimics the aged bone environment and leads to decreased bone
mass in mice, showing that a low TRP/high KYN diet leads to sig-
nificant bone loss and high marrow adiposity in mice, resembling an
aged bone phenotype (Hamrick et al., 2006; Refaey et al., 2017). We
also recently reported elevated KYN concentrations in the bone marrow
of aged humans (Kim et al., 2019).
KYN's negative effects on the skeletal system may be mediated by
cytokine and epigenetic factors that impact BMSCs. Stromal cell-de-
rived factor 1 (SDF-1 or CXCL12) (Carbone et al., 2017; Herberg et al.,
2013; Mortensen and Hill, 2015) is implicated in myriad stem cells
functions including cellular proliferation, differentiation, migration,
and homing to niche sites (Cheng et al., 2017; Bromage et al., 2014;
Yang et al., 2018a; Li et al., 2007; Broxmeyer et al., 2005). CXCL12 has
multiple splice variants, the most common of which are CXCL12α and
CXCL12β (Yu et al., 2006). Both isoforms act mainly through CXCR4
and CXCR7 (i.e., atypical chemokine receptor 3 [ACKR3]) receptors to
achieve various downstream effects (Reid et al., 2018; Quinn et al.,
2018; Sanchez-Martin et al., 2012). We previously reported that
CXCL12 levels decline in bone marrow interstitial fluid with aging,
while increasing in the peripheral circulation, which correlates with
deteriorating bone health in older subjects (Carbone et al., 2017;
Periyasamy-Thandavan et al., 2018). Our group and others have re-
ported that CXCL12 is important for osteogenic differentiation pri-
marally by augmenting the pro-osteogenic effects of BMP-2. CXCR4
signaling is required for the activation of the BMP-2R and increases
BMP-2 mediated osteogenesis (Yang et al., 2018a; Herberg et al.,
2014a; Herberg et al., 2015). Additionally, targeted deletion of CXCL12
BMSCs results in reduced trabecular bone content and increased bone
marrow adiposity (Tzeng et al., 2018). Regarding epigenetic factors,
histone deacetylases (Hdacs) are integrally involved in bone home-
ostasis. Hdacs remove acetyl groups from lysine residues in histones,
which changes chromatin structure and in turn affects gene expression
altering many signal transduction pathways. Histone deacetylase 3
(Hdac3) is expressed in osteoblasts and plays a critical role in bone
development by binding to the osteogenic transcription factor Runx2 to
regulate osteoblastic gene expression (Bradley et al., 2011). Conditional
deletion of Hdac3 in osteoprogenitor cells (Hdac3-CKO) causes a re-
duction in osteoblastic activity and produces a low bone mass pheno-
type with increased BM adipogenesis (Trivedi et al., 2007). Another
epigenetic factor that influences BMSC behavior is microRNAs
(miRNAs) via effects on cell cycle, apoptosis, proliferation, stem cell
maintenance, and differentiation (Khordadmehr et al., 2019; Cheng
et al., 2005; Goldar et al., 2015) (Farina et al., 2014) (Wang et al., 2010;
Skog et al., 2008; Valadi et al., 2007). MiRNAs are ~20 nucleotide
RNAs that bind to mRNAs and post-transcriptionally regulate gene ex-
pression of the targeted mRNAs. Pre-miRNAs are processed to generate
two partially complementary strands, the normally active guide strand
and the passenger strand that is typically degraded and inactive. Sev-
eral miRNAs play an important role in controlling osteogenic and os-
teoclastogenic differentiation in the bone marrow, making them valu-
able new diagnostic biomarkers for bone health (Kureel et al., 2014;
Vimalraj et al., 2014; Lee et al., 2013). We have identified one of these
as the passenger strand of the key osteogenic microRNA-29b-1 (miR-
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29b-1-5p). This novel passenger strand increases with age in human
and murine BMSCs (Hill et al., 2016; Periyasamy-Thandavan et al.,
2013; Baglio et al., 2013; Lee et al., 2016; Suh et al., 2013a; Shi et al.,
2016; Li et al., 2009; William and Hill, 2016). The guide strand (miR-
29b-1-3p) has been extensively documented to be critical in different
stages of bone formation and fracture healing (Lee et al., 2016; Li et al.,
2009; Suh et al., 2013b). Of interest miR-29b-1-3p (and other miR-29
family guide strands) target and suppress the CXCL12 regulator di-
peptidyl peptidase-4 (DPP4) (Shi et al., 2016). Therefore, this miRNA is
predicted to be central to local bone marrow DPP4 activity and CXCL12
ligand and proteolytic isoform levels. Current studies on miR-29b have
focused on the guide strand miR-29b-1-3p (previously miR-29b-1-1) (Li
et al., 2009). In contrast, the passenger strand miR-29b-1-5p (pre-
viously miR-29b-1-1*) has largely been considered to be a non-func-
tional byproduct of the miR biogenesis process. However, our group has
found miR-29b-1-5p to accumulate with aging in human and murine
BMSCs (Betel et al., 2010). Further, when it is expressed in BMSCs it can
induce aging-like actions targeting osteogenic genes like the CXCL12
axis, and based on in silico analysis, also Hdac3 (Betel et al., 2010).
In this paper, we describe three inter-related mechanisms (CXCL12,
Hdac3, miR-29b-1-5p) through which KYN affects BMSCs in aging.
These pathways are interconnected, and the crosstalk between them
appears to be complex and highly regulated. It also appears that KYN's
effect on CXCL12, miR-29b-1, and Hdac3 are all mediated through
binding and nuclear translocation of the xenogeneic AhR.
2. Materials and methods
2.1. Animals
C57BL/6J mice were either provided by the National Institute on
Aging (Bethesda, MD, USA) aged rodent colony or purchased from
Jackson Laboratories (Bar Harbor, ME, USA). Animals were maintained
at Augusta University in the Division of Laboratory Animal Services
Facility. All aspects of the animal research were conducted in ac-
cordance with the guidelines set by Augusta University Institutional
Animal Care and Use Committee (AU-IACUC) under AU-IACUC ap-
proved Animal Use Protocols. Mice were maintained on a standard 12-h
light – 12 h dark protocol and permitted water and food ad libitum.
2.2. Isolation and culture of murine BMSCs
Murine BMSCs were derived from 3, 6, 11, 18, and 27-month-old
male C57BL/6J mice at the Augusta University Stem Cell Core Facility.
The BMSC isolation process, as well as the MSC characterization and
multi-lineage potential (osteogenic, adipogenic and myogenic) have
been described previously (Herberg et al., 2013; Zhang et al., 2008). In
brief, six to eight mice of each age were euthanized by CO2 overdose
followed by thoracotomy. Whole bone marrow aspirates were flushed
from femora and tibiae and BMSCs isolated by negative im-
munodepletion using magnetic microbeads conjugated to anti-mouse
CD11b (#558013) and CD45R/B220 (#551513) (BD Biosciences
Pharmingen, San Diego, CA, USA), CD11c, and plasmacytoid dendritic
cell antigen (PDCA)-1 (#130-092-283 Miltenyi Biotec, Auburn, CA)
followed by positive immunoselection using anti-stem cell antigen
(Sca)-1 microbeads (#130-092-529 Miltenyi Biotec, Auburn, CA), ac-
cording to the manufacturer's recommendations. The enriched single-
age pooled BMSC populations were maintained in Dulbecco's Modified
Eagle Medium (#10-014-CM DMEM; Cellgro, Mediatech, Manassas, VA,
USA) supplemented with 10% heat-inactivated fetal bovine serum
(FBS) (#S11150 Atlanta Biologicals, Lawrenceville, GA, USA) and used
at 60–70% confluency.
To measure mRNA levels of some markers without culturing or
plastic adherence, directly isolated BMSCs were derived from young
adult (6–8 months) and geriatric (22–24 month-old) female C57BL/6J
mice. Long bones (i.e., humeri, femora, tibiae) were dissected from
mice and placed into mBMSC medium consisting of alpha MEM
(#41061 Gibco), 20% FBS, 1% antibiotic/antimycotic, and 1% non-
essential amino acids [NEAA] (#11140050 Gibco), on ice. BMSCs were
then extracted by flushing marrow and filtering through 70 μm cell
strainers.
2.3. Isolation and culture of human BMSCs
A direct-isolation procedure was used to rapidly capture human
BMSCs directly from bone. Bone marrow aspirates from the proximal
tibia (knee replacement surgery), proximal femur (hip replacement
surgery) or iliac crest (spinal fusion surgery) were collected as ortho-
paedic surgical waste under IRB approval in EDTA blood collection
tubes. The bone marrow aspirates were then run over a Ficoll gradient
to collect the buffy coat within 30 min of collection. CD271 positive
(+) hMSCs were then isolated from the nucleated cell layer using
CD271 MicroBead Kits (#130-092-283 Miltenyi Biotec, Auburn, CA)
according to the manufacturer's protocol to obtain a highly enriched
BMSC population within 2 h of bone marrow aspiration. The cells were
counted and frozen, or cultured for 1–2 passages prior to cryopre-
servation for in vitro cell culture studies. The isolated cells were first
confirmed by FACS analysis to be positive for CD73, CD90 and CD105
and negative for CD34, CD45 and CD11b. Corresponding isotype con-
trol antibodies were used when cells were sorted according to criteria
set by the International Society for Cellular Therapy (ISCT) to define
hMSCs (Cao et al., 2015).
Isolating CD271+ cells allows for the direct isolation of BMSCs
from orthopaedic patient's bone marrow aspirates within 2 h of col-
lection. This is in contrast to the standard BMSCs isolation process that
includes 1–2 day plastic adhesion followed by negative and positive
selection and an additional 2–3 week passaging. This is now a standard
rapid MSCs isolation method that both reduces the complexity of iso-
lation and maintains cell expression profiles as close to in vivo as
possible (Kuçi et al., 2019; Álvarez-Viejo, 2015; Cuthbert et al., 2015;
Cox et al., 2012; Poloni et al., 2009).
The isolated cells were tested for multilineage properties, i.e., their
capacities for osteogenic, adipogenic and chondrogenic differentiation
and the expression levels of key genes (qRT-PCR analysis) regulating
these differentiation pathways, including Runx2, Osx and ALP (osteo-
genic), PPARγ, and C/EBPβ and -α (adipogenic), and Sox-9, type I and
type II collagen (chondrogenic). Colony-forming unit-fibroblast (CFU-f)
assays were performed to calculate the population doubling capacity.
CD271+ MSCs were isolated directly from bone marrow aspirates,
washed with standard culture medium composed of DMEM medium
(#10-014-CM Corning), 1% antibiotics antimycotics (#15240-062 AA;
Invitrogen) and 15% FBS, with low glucose (1 g/l), transferred to
100 mm culture dish and incubated at 37 °C in a humidified atmosphere
in 5% carbon dioxide (CO2). After 24 h, the medium with non-adherent
cells is removed, and the adherent cells were carefully washed in DPBS
(Dulbecco's phosphate-buffered saline) (#SH30028 HyClone) and fur-
ther expanded in fresh culture medium. Culture-expanded CD271+
MSCs of passage 1–2 were used for in vitro studies.
2.4. KYN preparation and doses
Human and murine BMSCs were treated with different doses (10,
50, and 200 μM) of L-kynurenine (#K8625 Sigma-Aldrich). Different
KYN doses were freshly prepared before administration. Previous data
from the literature shows endogenously present KYN levels in the cul-
ture media of different cell types is highly variable, ranging from 5 to
60 μM and typically increases with time in culture (Opitz et al., 2011;
Yamamoto et al., 2019). Indeed, utilizing an ELISA kit (#E4629 Bio-
vision, Milpitas, CA) we identified that commercial DMEM media (#10-
014-CM Corning) itself contains approximately 3–5 μM of KYN (un-
published data). Other researchers have consistently reported various
specific dose-dependent effects using wide ranges of KYN doses
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(10–300 μM) (Kawasaki et al., 2014; Xiang et al., 2019). Moreover, a
recently published paper reported that different doses of KYN
(30–500 μM) significantly increased migration in 95D lung cancer cells
(Duan et al., 2019). Taking all these different caveats in consideration,
we wanted our data to represent three levels of Kyn: 10 μM (low dose
close to that of cell-free media and serum levels), 50 μM (medium dose
close to the previously reported conditioned media levels secreted by
various cell types in culture), and 200 μM (high dose that exceeds the
previously reported in vitro levels, falls within the range of KYN doses
previously used in literature, and is similar to the in vivo dose used in
our previous Kyn studies (Refaey et al., 2017).
2.5. Osteogenic differentiation assay
The ability of culture-expanded MSCs to differentiate into the os-
teogenic lineage was validated according to earlier described methods
(Herberg et al., 2013; Gregory et al., 2004). In brief, cells were plated in
12-well plates at 50000 cells/cm2 and cultured in DMEM for 24 h.
Culture medium was then aspirated and replaced with StemXVivo Os-
teogenic/Adipogenic Base Media (#CCM007 R&D Systems) supple-
mented with StemXVivo Human Osteogenic Supplement (#CCM008 R&
D Systems). Treatment-containing medium was replaced 2 times per
week. The early osteogenic differentiation marker, Alkaline Phospha-
tase, was assessed in cell culture media after 7 days using an Alkaline
Phosphatase Assay Kit (#ab83369 Abcam). After 3 weeks, osteogenic
differentiation was assessed by staining with Alizarin-Red Staining
Solution; (#TMS-008-C Millipore Sigma). The cells were fixed with
10% formalin for 20 min at room temperature (RT) and stained with
Alizarin-Red Staining Solution for 20 min at RT. Stained monolayers
were visualized by phase-contrast microscopy using an inverted mi-
croscope (Nikon, Melville, NY). Differentiation was quantified as pre-
viously described (Ripoll and Bunnell, 2009). In brief, cells were de-
stained using 10% cetylpyridinium chloride (#855561 Sigma-Aldrich)
and collected samples analyzed using a microplate reader at 570 nm.
2.6. Cell density assay
To determine whether KYN affected BMSCs density, we utilized a
Crystal violet Assay Kit (#ab232855 Abcam) according to the manu-
facturer's protocol. In brief, BMSCs were plated in 96 well plates at
5000 cells/well and cultured in DMEM for 24 h. Culture medium was
then aspirated and replaced with StemXVivo Osteogenic/Adipogenic
Base Media (#CCM007 R&D Systems) supplemented with StemXVivo
Human Osteogenic Supplement (#CCM008 R&D Systems) with or
without different doses of KYN (10, 50, 200 μM). After 3 days, the
culture media was removed and the cells were washed and stained with
the Crystal Violet Staining solution for 20 min at RT. Then, the staining
solution was removed and the remaining stain was solubilized for
20 min with the Solubilization Solution. Finally, the Crystal Violet stain
was quantified using a microplate reader at 595 nm.
2.7. Western blotting
Whole cell lysates of BMSCs were prepared in RIPA lysis and ex-
traction buffer (#89901 ThermoFisher Scientific) containing protease
and phosphatase inhibitor cocktail (Millipore Sigma). Protein con-
centration was determined using Pierce BCA Protein Assay Kit (#23225
ThermoFisher Scientific) and equal amounts (30 μg) of protein lysates
were subjected to SDS-PAGE using gradient 4–12% NuPAGE Bis-Tris
gels (#NP0321 Invitrogen) and transferred to 0.2 mm nitrocellulose
membranes using Power Blotter Select Transfer Stacks (#PB3310
ThermoFisher Scientific).
Membranes were blocked with 5% Bovine Serum Albumin (#A2153
Sigma-Aldrich) in TBST. Osteogenic and Histone deacetylation markers
were detected using specific primary antibodies (Table 1). Bound an-
tibodies were visualized with Pierce ECL detection system (#32106
ThermoFisher Scientific) on Amersham Imager 600 (GE Healthcare,
Pittsburgh, PA). The intensity of immunoreactive bands was quantified
using Image Lab (Bio-Rad, Hercules, CA).
2.8. Quantitative real time polymerase chain reaction (qRT-PCR)
The levels of 18S, CXCL12, CXCR4, ACKR3, IDO-1 and AhR mRNA
in human cells undergoing various treatments were assessed using
quantitative real-time PCR and TaqMan reagents. Total RNA was iso-
lated from BMSCs and then purified using the RNAeasy kit (#74106
Qiagen, SantaClarita, CA). Purified total RNA was reverse transcribed
with High-Capacity cDNA Kits (#4368814 USA – Applied Biosystems).
PCR reactions were performed using TaqMan Fast Advanced Master
Mix (#4444556 USA – Applied Biosystems). The pre-formulated assay
primers used in this study were individual gene-expression assays
(#A25576 Applied Biosystems) (Table 2). 18S was used as the en-
dogenous control for mRNA. The target gene was normalized using the
endogenous control to calculate ΔΔCt values. For real-time PCR, 2 μL of
the cDNA sample (100 ng/reaction), 10 μL TaqMan Fast Advanced
Master Mix, and 1 μL primer assay were mixed with 7 μL nuclease-free
water. All PCR reactions were performed in duplicate.
Gapdh, Hdac3, Hsd11b1, NcoR1, and RUNX2 mRNA levels were
assessed using quantitative real-time PCR and SYBR Green reagents.
Mouse cells cultured in 6-well plates for 7 days were lysed using TRIzol
reagent (#15596-018 Invitrogen), and total RNA was extracted using
protocols as previously described. Purified mRNA extracts were reverse
transcribed (RT; Bio-Rad C1000 Thermal Cycler, California, USA) to
cDNA using commercially available SuperScript III First-Strand
Synthesis RT reagents (#11752-050 Invitrogen). Gene expression was
determined by real-time semi-quantitative PCR analysis (qPCR; Bio-Rad
CFX Connect PCR System, California, USA) using 37.5 ng of cDNA per
15 μL well volume with QuantaBio PerfeCTa SYBR Green Supermix
(#95054-500 VWR) and SYBR Green gene specific primers (Table 3).
Gene expression levels were quantified using the comparative threshold
cycle (2-ΔΔCt) method. Transcript levels were normalized to the re-
ference gene Gapdh.
Murine miR-29b-1-5p and miR-29b-1-3p levels were assayed using
the TaqMan reagents mentioned above and the results were normalized
to U6 snRNA (USA – Applied Biosystems). For human miRNA analysis,
the expression levels of miR-29b-1-5p and miR-29b-1-3p were mea-
sured by miScript qPCR and were normalized to RNU-6 expression
(Qiagen, SantaClarita, CA). The catalog numbers for different TaqMan
and SYBR green primers are listed in Tables 2 and 3, respectively.
2.9. KYN enzyme linked Immunosorbent assay (ELISA)
Murine bone marrow derived mesenchymal stem cells (BMSCs) of 6
and 18 month old were seeded separately in 6-well flat bottom plates
(100,000 cells/well). The cells were grown in DMEM media supple-
mented with 10% fetal bovine serum and 1× of Antibiotic/Antimycotic
Solution (#15240062 Invitrogen) at 37 °C, 5% CO2 incubator. After
24 h and 48 h of incubation, a media sample was collected from each
cell line, centrifuged for 20 min at 1000 ×g at 4 °C, transferred to new
tube and stored in −80 °C until used. Kynurenine (KYN) ELISA Kit
(#E4629 Biovision, Milpitas, CA) was used to measure kynurenine
concentration in media samples by following the manufacturer's
Table 1
Specific antibodies used for WB protein analysis.
Protein Antibody company Catalog no.
β-Actin Sigma-Aldrich A2228
Hdac3 Abcam Ab7030
H4 Cell Signaling 2935P
Acetyl-H4 Cell Signaling 8647P
Runx2 Abcam ab76956
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instructions.
2.10. CXCL12α enzyme linked Immunosorbent assay (ELISA)
CXCL12α was measured as described previously (Carbone et al.,
2017; Herberg et al., 2013). Briefly, the CXCL12 capture antibody (R&D
Systems, Minneapolis, MN) was incubated in sodium bicarbonate buffer
overnight. Plates were blocked for 2h with 1% bovine serum albumin
(BSA) in PBS next day. Murine CXCL12α standards and samples were
incubated for 2h before incubating with the biotinylated anti-CXCL12α
detection antibody (#MAB350 R&D Systems). Streptavidin-horseradish
peroxidase (HRP) (#DY998 R&D Systems) was incubated for 20min
followed by the substrate reagent (#DY999 R&D Systems) for 20min.
2N sulfuric acid was added to stop the enzymatic color reaction and
absorbance was read at 450nm. CXCL12α protein expression was cal-
culated using standard curves and normalized to total protein, which
was quantified using the Pierce BCA Protein Assay Kit. For age-related
CXCL12 plasma and bone marrow interstitial fluid levels one set of male
C57BL/6 mice from six different age groups (3, 6, 12, 18, 24, and
29 months of age), 10 mice per age group, were obtained from the aged
rodent colony at the National Institute on Aging. Our sample is there-
fore a cross-sectional as opposed to a longitudinal one. Mice were
housed individually and all were fed ad libitum on NIH31 diet. Blood
was collected via cardiac puncture once mice were euthanized, as per
the IACUC protocol, in EDTA tubes which were centrifuged as pre-
viously described to obtain plasma, and stored frozen at −80 °C. Hu-
meri and tibiae were collected to isolate bone marrow interstitial fluid
via flushing of the bone marrow space as previously described (Herberg
et al., 2013; Herberg et al., 2014b; Ding et al., 2007).
2.11. Mimic and inhibitor miRNA transfection and AhR inhibition
BMSCs were transfected with either a mimic or inhibitor (antag-
omir) for miR-29b-1-5p (Cat #YM00471910 and #YI04101505 Qiagen,
SantaClarita, CA) according to the manufacturer's protocol. The re-
commended controls for miR-29b-1-5p mimic and inhibitor were used
(Cat #YM00479902 and Cat #YI00199006 In brief, cells were seeded at
25,000–30,000 cells/well in a 24-well plate in 500 μl of an appropriate
culture medium containing 10% serum and no antibiotics. For 1–3 h
until transfection, cells were incubated under normal growth conditions
(typically 37 °C and 5% CO2). miRNA mimics or inhibitors were
resuspended prior to transfection in RNase-free water to achieve the
recommended concentration of 20 μM. The miRNA inhibitor and mimic
were diluted in Opti-MEM media to give a final miRNA inhibitor con-
centration of 100 nM and final miRNA mimic concentration of 1 nM for
normal transfection experiments and 5 nM for 3′-UTR luciferase assays.
HiPerFect transfection reagent (#301705 Qiagen, SantaClarita, CA)
was added to the diluted miRNA mimic/inhibitor and mixed by vor-
texing. Then, the samples were incubated for 5–10 min at room tem-
perature (15–25 °C) to allow the formation of transfection complexes.
The complexes were added drop-wise onto the cells. BMSCs were in-
cubated with the transfection complexes under their normal growth
conditions for 6 h, and then the transfection media was removed and
replaced with serum-free media containing the desired treatment. Cell
culture media samples were collected for analysis, and cells were lysed
and mRNA collected at the end of the incubation period. Negative
control miR inhibitor was used as a negative control for miR-29b-1-5p
inhibitor, and AllStars Hs Cell Death Control siRNA was used as a ne-
gative control for miR-29b-1-5p mimic. For AhR inhibition, AhR an-
tagonist, CH-223191 (#C8124 Sigma-Aldrich) was dissolved in DMSO
to make a 2 mg/mL stock solution, and a final concentration of 2 μg/mL
was added to BMSCs culture medium (Asai et al., 2018; Yang et al.,
2018b). A second AhR antagonist, 3′,4′-dimethoxyflavone (DMF)
(#D6571 Sigma-Aldrich), was also used (10 μM).
2.12. Luciferase assay
Culture-expanded human BMSCs were co-transfected with a either
wild type or mutated miTarget miRNA 3′-UTR luciferase functional
reporter plasmid for CXCL12 or Hdac3 (#HmiT088617-MT06 and
#HmiT115117-MT06 GeneCopeia, Rockville, MD) and either miR-29b-
1-5p mimic or mimic control (#YM00471910 and #YM00479902
Qiagen, SantaClarita, CA) using Lipofectamine 3000 reagent
(#L3000015 ThermoFisher Scientific, Waltham, MA). Mutated plas-
mids for CXCL12 (at 3 predicted target sites) and Hdac3 (at one pre-
dicted target site) were custom made and purchased from Genecopeia
(Rockville, MD). The predicted binding sites for miR-29b-1-5p were
determined using the prediction software and database MiRanda (Betel
et al., 2010). Dual luciferase activity of the CXCL12 and Hdac3 reporter
plasmids were measured 24 h after transfection using Luc-Pair™ Duo-
Luciferase High Sensitivity Assay Kit (#LF004 GeneCopeia, Rockville,
MD) according to the manufacturer's protocol, and compared to non-
targeting miR-transfected controls. The Duo-Luciferase HS Assay Kit
was used because it eliminates the need for separate controls to de-
termine if differences are due to differential vector uptake and to nor-
malize the outcomes, e.g. the use of beta-galactosidase which is typi-
cally used for normalization to luciferase counts. This is done by
including Firefly luciferase (FLuc) and Renilla luciferase (RLuc), where
the RLuc signal is used as a control for how much construct was taken
into the cell while FLuc signal is used for measuring transcriptional
activation. The final signal is expressed as FLuc to RLuc ration to
compensate for different transfection efficiencies.
2.13. Statistical analysis
Experiments were performed at least three independent times. Data
are expressed as means± SD unless stated otherwise. Data were ana-
lyzed using GraphPad Prism 7.0 software (GraphPad Software Inc., La
Jolla, CA, USA). Student t-test was used for comparisons between two
groups and analysis of variance (ANOVA) followed by Tukey's multiple
comparison test was used for comparisons between 3 or more groups.
Null hypotheses were rejected at the 0.05 level. Statistical significance
was determined and shown in figures and figure legends.
Table 2
TaqMan mRNA and miRNA pre-formulated gene specific
primer assay IDs.
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SYBR Green mRNA gene specific primer sequences.
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3. Results
3.1. CXCL12 axis is downregulated with both aging and KYN treatment in
murine and human BMSCs
We previously showed that CXCL12 is essential in BMSC osteogen-
esis (Herberg et al., 2013; Herberg et al., 2015). We also established
that KYN contributes to skeletal aging mechanisms and affects the
balance between osteogenic and adipogenic differentiation in BMSCs
(Refaey et al., 2017). For our initial experiment, we compared the ef-
fects of both aging and KYN on the CXCL12 axis. First, we utilized an
established ELISA to measure CXCL12 protein levels in murine samples
from bone marrow interstitial fluid and plasma at different ages of
C57BL/6J mice (n = 10 per group). Levels of CXCL12 significantly
declined with aging in bone marrow interstitial fluid starting around
12 months of age, while significantly rising in the peripheral circulation
after that same age (Figs. 1A, B). The rise in plasma CXCL12 was similar
to what we previously observed in human plasma (Carbone et al.,
2017), while the decrease in CXCL12 levels in BM interstitial fluid in
aged subjects was similar to our previous BM results in mice
(Periyasamy-Thandavan et al., 2018). Interestingly, in our in vitro
system, BMSCs isolated from 18 months old mice showed significantly
increased levels of KYN in their cell culture media compared to BMSCs
isolated from 6 months old mice after 48 h of incubation (Fig. 1C).
We also assessed how mRNA expression of CXCL12 and its main
receptor, CXCR4, changed in BMSCs with aging. We used BMSCs iso-
lated from mice at the ages of 6, 11, and 27 months. These ages cor-
respond to adult (6 months), adult near the peak accumulation of bone
mass prior to bone loss (11 months), which is prior to significant
changes in CXCL12 protein levels in the BM interstitial fluid, and
Fig. 1. Aging and kynurenine downregulate CXCL12 axis. (A) CXCl12 protein levels in murine plasma from 3, 6, 12, 18, 24, and 29 months-old mice (n = 10). (B)
CXCl12 protein levels in murine bone marrow interstitial fluid from 3, 6, 12, 18, 24, and 29 months-old mice (n = 10 mice per group). (C) Kynurenine level (μM) in
cell culture media of BMSCs isolated from 6 and 18 months old mice (n = 3). (D,E) mRNA levels of CXCL12 (D) and CXCR4 (E) in BMSCs isolated from 6, 11, and
27 months-old mice (n= 4 for 6 and 11 months old mice and n= 7 for 27 months old mice). (F) CXCL12 protein levels in BMSCs isolated from pooled 6 months-old
mice after treatment with 200 μM kynurenine for 48 h (n = 4). (G-I) mRNA levels of CXCL12 (F), and CXCR4 (G) and ACKR3 (H) after treatment with 50 and 200 μM
kynurenine for 6 h (n = 3). Data presented as mean ± SD. Data analysis was done using one way ANOVA for panels A, B, D, E, F, G, H, and I, and using unpaired t-
test for panel C. Data presented as mean ± SD. *P<0.05, **P<0.01, ***p<0.001, ****p<0.0001.
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elderly (27 months), at which time there is significant age-associated
bone loss and a significant reduction in BM interstitial fluid CXCL12
(Hamrick et al., 2006; Refaey et al., 2017). CXCL12 mRNA levels sig-
nificantly declined to 50% at 27 months, while CXCR4 mRNA levels
were significantly reduced earlier at both 11 and 27 months of age
compared to 6 month-old mice (Figs. 1D, E).
Since KYN levels are linked to aging, we then tested if KYN treat-
ment of BMSCs had a similar effect. BMSCs isolated from 3-, 6-, and 18-
month-old mice showed significantly lower CXCL12 protein levels in
the cell culture media upon treatment with 200 μM KYN compared to
control. CXCL12 protein secreted in culture media from BMSCs isolated
from young mice (6 months) was significantly reduced, almost 80%,
when treated for 48 h with 200 μM KYN (Fig. 1F). Secretion of CXCL12
from BMSCs of 3 and 18 months old mice was also decreased with KYN
(Supp. Figs. 1A,B). Consistently, there was a significant decrease in
CXCL12 mRNA expression in the BMSCs as early as 6 h after treatment.
Concomitant with reduction in CXCL12 expression, mRNA expression
of the receptors, CXCR4 and CXCR7, was also decreased by almost
30–50% (Fig. 1G–I). BMSCs isolated from 6-month-old mice showed
similar changes in CXCL12 mRNA expression at later time points with a
significant decrease at 48 h post-treatment (Supp. Fig. 1C).
3.2. KYN attenuated osteogenesis and osteogenic gene expression in BMSCs
In vivo experiments have shown that KYN accumulates with aging
and induces bone loss (Refaey et al., 2017). To establish if, at least in
part, KYN achieves this function via inhibition of BMSC osteogenesis,
we treated BMSCs isolated from 6- and 18-month-old mice with dif-
ferent doses of KYN (10, 50, 200 μM). Using osteogenic differentiation
media for 21 days and Alizarin Red staining, KYN doses inhibited os-
teogenic differentiation in BMSCs from 6-month-old mice in a dose
dependent manner, with the high KYN dose (200 μM) showing a sig-
nificant 50% decrease (Fig. 2A). After 14 days, the high KYN dose also
showed significant inhibition of minerlization with Alizarin Red
staining (Supp. Fig. 2A), as well as intermittent doses (Supp. Fig. 2D).
The early effects of KYN on osteogenic differentiation of BMSCs isolated
from 6 months old mice were confirmed using alkaline phosphatase
activity assay after 7 days of incubation in osteogenic differentiation
media (Fig. 2B). To determine whether this KYN effect was in fact due
to inhibition of osteogenesis and not an effect on cell density, a crystal
violet assay assessed KYN cytotoxicity and showed that none of the
doses of KYN (10. 50, and 200 μM) affected cell proliferation as de-
termined by the number of BMSCs when cultured under the same
conditions as the osteogenic differentiation experiments (Supp.
Fig. 2C).
Next, directly isolated BMSCs (i.e., without in vitro expansion/
passaging prior to experimentation) from young and old mice
(6–8 months versus 22–24 months) were used to assess how KYN affects
their osteogenic differentiation marker expression. Basal expression
level of the osteogenic marker, Runx2 was significantly lower in os-
teogenically-cultured BMSCs isolated from old mice compared to si-
milarly cultured BMSCs isolated from young mice. We also found that
treating BMSCs from either younger or older mice with KYN sig-
nificantly reduced their mRNA levels of Runx2, resembling the effect of
aging. Runx2 protein expression was also significantly downregulated
after 7 days of KYN treatment in osteogenic differentiation media
(Fig. 2C, D).
3.3. The KYN treatment phenotype resembles aging in upregulating
CXCL12-targeting miR-29b-1-5p
To determine how in vitro administration of KYN induced a phe-
notype reminiscent of organismal aging in terms of miR-29b-1 expres-
sion, we measured miR-29b-1-5p levels in BMSCs from young versus
old mice. BMSCs isolated from aged mice had significantly higher levels
of miR-29b-1-5p and significantly lower levels of miR-29b-1-3p com-
pared to BMSCs from younger mice (Fig. 3A, B). As in the mice we also
found that miR-29b-1-5p levels in aged human MSCs were significantly
Fig. 2. Kynurenine inhibits BMSCs osteogenic dif-
ferentiation. (A) Optical density of alizarin red os-
teogenic assay staining and corresponding wells of
BMSCs isolated from pooled 6 months-old mice after
treatment with different doses of kynurenine (10, 50,
and 200 μM) for 21 days (n = 6). (B) Alkaline
Phosphatase (ALP) activity relative to control in
BMSCs isolated from pooled 6 months-old mice
treated with different doses of kynurenine (10, 50,
and 200 μM) for 7 days (n = 6) (C) mRNA levels of
Runx2 in BMSCs isolated from young (6–8 months-
old) and old (22–24 months-old) mice, in osteogenic
differentiation medium with or without 200 μM ky-
nurenine for 7 days (n = 3 mice per group). (D)
Protein levels of Runx2 in BMSCs isolated from
6 months mice after incubation in osteogenic dif-
ferentiation medium with or without 200 μM ky-
nurenine for 7 days. Data presented as mean ± SD.
Data analysis was done using one way ANOVA for
panels A, B, and C, and using unpaired t-test for
panel D. *P<0.05, **P<0.01, ***p< 0.001,
****p< 0.0001.
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upregulated in aged vs. adult MSCs, but different from the murine the
miR-29b-1-3p levels were not significantly changed in humans with age
(Supp. Fig. 3A).
We then measured miR-29b-1-5p levels in murine BMSCs from 6-
month-old mice with or without KYN treatment for 1, 3, 6, 24, and 48 h.
KYN transiently, upregulated miR-29b-1-5p beginning at 24 h (Fig. 3C).
The levels of miR-29b-1-5p expression in response to KYN was almost
back to normal by 48 h.
To confirm that increased levels of miR-29b-1-5p mediated KYN's
effect on the CXCL12 axis, rather than being an independent down-
stream effect of KYN, we transfected BMSCs isolated from 6-month-old
mice with a miR-29b-1-5p inhibitor, and treated them with KYN for
Fig. 3. Kynurenine upregulates pro-aging and CXCL12-targeting miR-29b-1-5p. (A,B) miR-29b-1-5p (A) and miR-29b-1-3p (B) levels in BMSCs isolated from 11
versus 27 months old (n = 4 for 11 months old mice and n = 7 for 27 months old mice). (C,D) miR-29b-1-5p levels (C) and miR-29b-1-3p levels (D) in BMSCs
isolated from pooled 6 months-old mice after treatment with 200 μM kynurenine for 1, 3, 6, 24 and 48 h (n = 3). (E,F) CXCL12 levels in BMSCs isolated from
6 months old mice after treatment with 200 μM kynurenine with or without transfection with miR-29b-1-5p inhibitor (E) or miR-29b-1-5p mimic (F) (n = 8 for
inhibitor and n = 4 for mimic). (G) Luciferase activity of CXCL12 reporter plasmids (wild type and mutant) after transfection with miR-29b-1-5p mimic relative to
luciferase activity of wild type CXCL12 reporter plasmid after transfection with miRNA mimic control for 24 h (n = 3). Data presented as mean ± SD. Data analysis
was done using one way ANOVA for panels E, F amd G, using two way ANOVA for panels C and D, and using unpaired t-test for panels A and B. *P< 0.05,
**P< 0.01, ***p< 0.001, ****p< 0.0001.
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24 h. The miR-29b-1-5p inhibitor alone did not significantly upregulate
CXCL12 protein level when there was low basal levels of miR-29b-1-5p
to start with. However, it restored CXCL12 protein levels when com-
bined with 200 μM KYN, which by itself increased miR-29b-1-5p and
significantly downregulated CXCL12 protein levels (Fig. 3E). We fur-
ther confirmed this result by treating the same BMSCs with 200 μM
KYN in the presence or absence of the miR-29b-1-5p mimic. Con-
sistently, both KYN and the miR-29b-1-5p mimic significantly down-
regulated CXCL12 protein levels by almost 30%. Further, combining
both miR-29b-1-5p and KYN together lead to a significant almost a 40%
inhibition of the CXCL12 protein level (Fig. 3F).
To determine whether miR-29b-1-5p's effect on CXCL12 was direct
or indirect, we utilized a 3′-UTR Duo-Luciferase assay, which controls
for vector uptake and transcriptional regulation in the same assay. A
reporter plasmid for wild type CXCL12 3′-UTR and another reporter
plasmid for CXCL12 3′-UTR mutated at all three potential binding sites
for miR-29b-1-5p according to the target prediction database Miranda
(Miranda et al., 2006) (Table 4) were used to assess whether the miR-
29b-1-5p directly targets the predicted binding sites. Transfection of
murine BMSCs with the miR-29b-1-5p mimic resulted in a significant
reduction (almost 30%) in the luciferase activity of the CXCL12 reporter
plasmid. When the wild type CXCL12 3′-UTR was replaced with the
mutated CXCL12 3′-UTR, the luciferase activity was significantly in-
creased indicating that miR-29b-1-5p could not bind and inhibit
CXCL12 luciferase activity (Fig. 3F).
3.4. KYN and miR-29b-1-5p differentially modulated Hdac3 levels
We previously demonstrated that administration of KYN in vivo
downregulates the levels of Hdac3 as well as its cofactor NCoR1 (Refaey
et al., 2017). We further showed that Hdac3 plays an important role in
the regulation of osteogenic and adipogenic differentiation in BMSCs in
aging (Refaey et al., 2017; Razidlo et al., 2010). Here, we measured the
basal mRNA levels of Hdac3 and its cofactor NcoR1 in BMSCs isolated
from young adult mice versus old mice. When BMSCs were grown in
osteogenic differentiation medium for 7 days, the mRNA levels of these
two markers were downregulated in murine BMSCs with aging. In ad-
dition, treatment with KYN significantly downregulated mRNA levels of
both markers in young and old mice (Fig. 4A, B).
To establish the relationship between miR-29b-1-5p levels and
Hdac3 levels, we measured Hdac3 mRNA expression in cells transfected
with either the miR-29b-1-5p mimic or the miR-29b-1-5p inhibitor.
Consistently, miR-29b-1-5p mimic significantly downregulated, while
miR-29b-1-5p inhibitor significantly upregulated, Hdac3 mRNA levels
(Fig. 4C, D).
To determine whether the effect of miR-29b-1-5p on Hdac3 is direct
or indirect, we designed another 3′-UTR Duo-Luciferase assay using
wild type and mutated Hdac3 3′-UTR vector plasmids. We found that
miR-29b-1-5p significantly reduced luciferase activity for the wild type
Hdac3 3′-UTR, and had no effect on the mutated Hdac3 3′-UTR,
confirming that miR-29b-1-5p acts directly on Hdac3 via the predicted
binding site (Miranda database) (Miranda et al., 2006) (Fig. 4E)
(Table 4).
We also measured Hdac3 protein expression and H4 acetylation
levels in response to 200 KYN μM or miR-29b-1-5p mimic to confirm
our previous results and found that consistent with our mRNA data,
both KYN and miR-29b-1-5p inhibited Hdac3 protein levels and we
demonstrated the expected downstream functional effect of Hdac3
suppression as evidenced by the significant increase in H4 acetylation
(Fig. 4G, H).
3.5. AhR mediates the effects of KYN on CXCL12
KYN has been shown to act through binding to the aryl hydrocarbon
receptor (AhR), which then translocates to the nucleus (Beischlag et al.,
2008). We tested if the AhR receptor was mediating KYN's effects on
CXCL12 protein levels, and on CXCL12, CXCR4, and ACKR3 mRNA
levels. We utilized the AhR antagonist 3′,4′-dimethoxyflavone (DMF),
and found that after 48 h of treatment, KYN significantly reduced se-
creted CXCL12 in the cell culture media of BMSCs from 6-month-old
mice, and that co-treatment with DMF was able to restore CXCL12
protein level (Fig. 5). Of translational importance, KYN treatment (50
and 200 μM) downregulated secreted CXCL12 from human BMSCs level
and the AhR antagonist CH-223191 restored it within 24 h (Supp.
Fig. 2B).
3.6. CXCL12 regulates IDO-1 and AhR mRNA levels
To test whether there was cross-talk between CXCL12 and KYN
whereby CXCL12 could suppress KYN-related pathways, we treated
BMSCs isolated from 6-month-old mice with 200 ng/mL CXCL12.
Ttreatment with CXCL12 significantly downregulated the mRNA levels
of AhR after 6 h and IDO-1, the gene encoding an enzyme that can
generate KYN, after 24 h suggesting that cross-talk exists (Fig. 6A, B).
4. Discussion
Tryptophan metabolism directly through the KYN pathway is in-
volved in the regulation of key physiological functions such as im-
munity, CNS/neuronal function, gastrointestinal homeostasis and we
now recognize in bone metabolism. Metabolic dysregulation in dis-
orders affecting these areas including aging, cancer, and neurodegen-
erative disease have led to significant clinical-translational interest and
even clinical trials targeting the KYNP pathway, specifically KYN, its
downstream metabolites and the AhR signaling pathway that responds
to KYN and its metabolites (Platten et al., 2019). Based on our work,
and that of others, it is now clear that this system is also critically in-
volved in osteoporosis and age-related bone loss. Here we help de-
lineate the mechanisms linking KYN and bone loss.
Osteoporosis is a bone disease characterized by a decrease in the
Table 4
Sequences of predicted binding sites between miR-29b-1-5p and the 3′-UTR of Hdac3 and CXCL12 according to MiRanda database. The miR-29b-1-5p sequence is the
top of each pairing.
Target accession Score miRNA start-end 3′utr start-end 3′-miRNA-5′-alignment-5′-utr3-3′
Hdac3 (NM_001355039) 122.00 2–23 83–106
CXCL12 (NM_000609) 163.00 2–22 32–54
CXCL12 (NM_000609) 151.00 3–22 2858–2880
CXCL12 (NM_000609) 141.00 2–23 558–582
A.M. Elmansi, et al. Bone Reports 12 (2020) 100270
9
ratio of bone formation to bone resorption with aging. Osteoporosis is
mostly asymptomatic during the first few years which makes early di-
agnosis more difficult (Phetfong et al., 2016). Currently available
treatments for osteoporosis can be associated with a wide range of side
effects (Antebi et al., 2014). A key barrier to preventing osteoporosis or
developing efficient new treatments is understanding the mechanisms
underlying the aging-related deterioration in bone health and
subsequent progression of osteoporosis. Our group and others have
demonstrated that osteoporosis is - at least in part - a stem cell disease
(Infante and Rodriguez, 2018; Herberg et al., 2015; Antebi et al., 2014).
This study aimed to investigate molecular pathways triggering age-as-
sociated changes in the bone marrow stem cell populations that could
lead to osteoporosis and thus may represent a new therapeutic target.
Osteogenic differentiation is critical in bone aging; as we age, there
Fig. 4. Kynurenine downregulates Hdac3 and its cofactors. (A,B) mRNA expression levels of (A) Hdac3 and (B) NcoR1 in BMSCs isolated directly from young and old
mice and cultured in osteogenic differentiation medium with or without 200 μM kynurenine for 7 days (n = 3). (C,D) mRNA expression levels of Hdac3 in BMSCs
isolated from pooled 6 months-old mice and transfected with either (C) miR-29b-1-5p mimic or (D) miR-29b-1-5p inhibitor compared to their respective controls
(n = 3). (E) Luciferase activity of Hdac3 reporter plasmids (wild type and mutant) after transfection with miR-29b-1-5p mimic relative to luciferase activity of wild
type Hdac3 reporter plasmid after transfection with miRNA mimic control for 24 h (n = 3). (F,G) Protein levels of Hdac3 (F) and H4 acetylation (G) in BMSCs
isolated from pooled 6 months-old mice after incubation in osteogenic differentiation medium with or without 200 μM kynurenine for 7 days. Data presented as
mean ± SD. Data analysis was done using one way ANOVA for panel E, using two way ANOVA for panels A and B, and using unpaired t-test for panels C, D, F, and G.
*P< 0.05, **P< 0.01, ***p<0.001, ****p< 0.0001.
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is a shift in BMSCs from osteogenic to adipogenic differentiation
(Infante and Rodriguez, 2018). Our group and other groups have re-
ported the beneficial role of CXCL12α and β in the osteogenic differ-
entiation of BMSCs (Yang et al., 2018a; Herberg et al., 2014a; Herberg
et al., 2015). We have found that increased KYN levels, as well as an
elevated KYN to TRP ratio, contribute to reductions in BMSCs osteo-
genesis and subsequent decreased bone formation in association with
aging (El Refaey et al., 2015; Kim et al., 2019). We have previously
reported increased serum and bone marrow levels of KYN with aging in
humans (Refaey et al., 2017) (Kim et al., 2019). While the specific
mechanism of age-related increases in KYN levels in different tissue
compartments is still not fully understood, the elevated KYN levels may
be due to upregulated local IDO activity with aging, as well as increased
ROS mediated conversion of tryptophan to KYN. These, or potentially
other mechamisms can lead to higher KYN levels and an increase in the
KYN/TRP ratio (Souza et al., 2018; Sas et al., 2018). KYN also down-
regulates Hdac3 and its cofactor NcoR1 which increases the degree of
adiposity in murine bone marrow together with reducing bone mass
(Refaey et al., 2017). We also recently assessed an array of miRNAs that
are upregulated in human BMSCs with aging, identifying miR-29b-1-5p
as a key miRNA involved in inhibiting osteogenesis with age (Hill et al.,
2016; Periyasamy-Thandavan et al., 2013; Baglio et al., 2013; Lee et al.,
2016; Suh et al., 2013a; Shi et al., 2016; Li et al., 2009; William and
Hill, 2016; Periyasamy-Thandavan et al., 2012). Here, we investigate
how these different anti-osteogenic pathways interact, underscoring
new biomarkers that can be targeted for clinical intervention to prevent
or treat osteoporosis at the stem cell level.
Our results here confirm that KYN inhibits BMSC osteogenesis and
downregulates osteogenic gene expression. This is in agreement with
work from Dinçel et al., who showed a significant correlation between a
high KYN/TRP ratio and the incidence of osteoporotic hip fracture
(Dincel et al., 2017). We have also shown that KYN levels and the KYN/
TRP ratio in the human bone marrow microenvironment are increased
with age (Kim et al., 2019). More importantly, we showed that subjects
with increased bone fragility, marked by decreased total femur BMD
and increased markers of bone resorption, have significantly higher
KYN levels and KYN/TRP ratios than those without (Kim et al., 2019).
Another group demonstrated that high levels of peripheral KYN and
AhR are significantly correlated with decreased bone strength, in con-
trast high central KYN levels in the frontal cortex of the brain are
correlated with increased bone strength (Kalaska et al., 2017a; Kalaska
et al., 2017b). These investigators believe that similar to serotonin,
another TRP metabolite, KYN can exert opposing effects on bone for-
mation depending on its site of action (Kalaska et al., 2017b; Ducy and
Karsenty, 2010).
The identification of mechanisms underlying KYN's anti-osteogenic
effects has been limited. Here, we demonstrate potential novel me-
chanisms based on downregulation of CXCL12 axis mRNA expression
and protein levels, via KYN ligand signaling through the AhR and
mediated by epigenetic changes in miRNAs and Hdac3. The decrease in
CXCL12 protein levels in response to KYN treatment and our previous
findings indicating that CXCL12 is important for osteogenesis, in turn
support the theory that KYN inhibits BMSCs osteogenesis via down-
regulation of the CXCL12 axis. We also found that KYN-mediated
downregulation of CXCL12 mimics the decline in CXCL12 protein levels
in human and murine bone marrow interstitial fluid with aging. The
reason for the corresponding age-related increase in CXCL12 levels in
murine and human plasma is not clear, but it could be due to summing
of inflammatory responses throughout the body in the plasma, or to
regulated compartmentalized changes in CXCL12 expression that are
different in the bone marrow versus plasma, and/or to an accumulation
of DPP4-cleaved non-CXCR4-activating CXCL12 in plasma subsequent
to feedback (Carbone et al., 2017; Ding et al., 2007; Elmansi et al.,
2019). Recently, links between AhR signaling and both CXCR4 and
ACKR3 levels have been suggested, where high AhR expression was
correlated with high expression of CXCR4 in breast tumors (Vacher
et al., 2018), and hepatic toxicity in response to AhR activation was
mediated, at least in part, by changes in ACKR3 mRNA levels (Watson
et al., 2017). Another potential link between the KYN pathway and the
CXCL12 axis, is the reported IDO- and tryptophan-mediated regulation
of CXCR4 expression and responsiveness to chemokines in dendritic
cells (Hwang et al., 2005).
KYN may achieve its anti-osteogenic effects in part by upregulating
Fig. 5. AhR antagonist inhibits kynurenine-induced CXCL12 downregulation.
CXCL12 protein levels in BMSCs isolated from pooled 6-month-old mice after
treatment for 48 h with 100 or 200 μM kynurenine with or without 10 μM of
AhR-antagonist 3′,4′-Dimethoxyflavone (DMF) (n = 3). Data presented as
mean ± SD. Data analysis was done using unpaired t-test. **P<0.01.
Fig. 6. CXCL12 regulates mRNA levels of IDO-1 and
AhR. (A,B) mRNA expression levels of (A) IDO-1, and
(B) AhR after treatment with CXCL12 (200 ng/mL)
for 24 and 6 h respectively (n = 4). Data presented
as mean ± SD. Data analysis was done using one
way ANOVA for panel C, and using unpaired t-test
for panels A and B. *P< 0.05, ***p< 0.001,
****p< 0.0001.
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miR-29b-1-5p, which targets CXCL12 and other osteogenic genes. We
noticed that changes in miR-29b-1-5p in response to KYN treatment of
200 μM peaked around 24 h and was almost back to basal level by 48 h,
which is expected due to the transient on/off nature of miRNA reg-
ulation (Bail et al., 2010; Zhang et al., 2012; Rüegger and Großhans,
2012). This miRNA upregulation supports the idea that increased KYN
levels with age may be a key regulator of the age-associated decrease in
osteogenesis. In this study, we focused mainly on miR-29b-1-5p since, it
targeted both CXCL12 and Hdacs, a second distinct epigenetic reg-
ulatory system. We had in silico evidence that miR-29b-1-5p targets
position 278–302 of the Hdac3 3′ UTR (Miranda et al., 2006). We
confirmed here, for the first time that this miRNA directly targets and
down-regulates both Hdac3 and CXCL12. Whether KYN can down-
regulate CXCL12 independently from miR-29b-1-5p is yet to be de-
termined. We found that KYN's effect on the CXCL12 protein level is
attenuated by the use of a miR-29b-1-5p (antagomir) inhibitor and
increased by the use of the miR-29b-1-5p mimic. This is further evi-
dence that miR-29b-1-5p is involved in KYN's downregulation of
CXCL12. This age-associated miRNA upregulation supports the idea
that increased KYN levels with age may be a key regulator of the age-
associated decrease in osteogenesis and may be linked to aging in other
systems.
The effect of KYN on miR29b-1-5p supports results from other
groups that miR-29b may play a role in osteoarthritis development
through inhibiting the expression of collagen I by chondrocytes and
collagen III by BMSCs (Mayer et al., 2017). We also found that miR-29b-
1-5p and miR-29b-1-3p levels change in opposite directions in mice
with aging. This is interesting, because Feichtinger et al. (Feichtinger
et al., 2018) found that high levels of miR-29b-1-3p are associated with
healthy bone microstructure and histomorphometry. In previous work
on human BMSCs, we only observed an increase in the miR-29b-1-5p
passenger strand with aging without a concomitant decrease in the
miR-29b-1-3p guide strand (Supp. Fig. 3C) (Periyasamy-Thandavan
et al., 2012); thus, there may be a difference between human and
murine age-associated expression of the guide and passenger strand
levels with the regulation of the 5p arm being more critical in aging
humans. miR-29b is not the only miRNA bone marker that shows op-
posing effects of its guide and passenger strands on bone health, as miR-
500a-3p was shown to have a positive correlation with bone surface, as
well as mineral apposition rate, while miR-500a-5p was shown to play
an inhibitory role in osteogenic differentiation and was reported as a
novel biomarker for fracture risk in postmenopausal women
(Feichtinger et al., 2018; Heilmeier et al., 2016). These observations
support the idea that in pathologies, including aging, there may be a
dysregulation of the microRNA processing leading to significant
changes in the targeting of mRNAs.
Importantly, KYN also downregulates Hdac3 and its cofactor NcoR1;
an effect that we previously linked to decreased osteogenesis and in-
creased adipogenesis in murine bone marrow (Refaey et al., 2017;
Razidlo et al., 2010). Hdac3 plays a critical role in the process of en-
dochondral ossification and bone matrix remodeling. Loss of Hdac3 in
osteochondral progenitors leads to an osteopenic phenotype from im-
paired bone formation and increasing marrow adiposity, and postnatal
inducible conditional knockout of chondrocyte Hdac3 leads to several
skeletal abnormalities as well as increased osteoclastogenesis (Razidlo
et al., 2010; Carpio et al., 2016; Gordon et al., 2015; Feigenson et al.,
2017; McGee-Lawrence et al., 2016). These studies all implicate Hdac3
as a crucial mediator of endochondral ossification, particulary in the
context of aging. It is also important to note that Hdac3 plays an im-
portant role in adipogenesis, where lower Hdac3 levels correlated with
an increase in bone marrow fat (Razidlo et al., 2010). This effect could
explain the increase in bone marrow adipose tissue we previously
Fig. 7. Proposed pathway of kynurenine effects on BMSCs. Aging upregulates activity of IDO1 which converts tryptophan to kynurenine. Kynurenine is then taken up
by BMSCs and binds to cytoplasmic AhR. Upon binding, ligand-bound AhR is transported into the nucleus where it forms a complex with Aryl hydrocarbon receptor
nuclear translocator (ARNT). The newly formed complex acts as a transcription factor and downregulates Hdac3 and CXCL12 transcription while upregulating miR-
29b-1-5p. Hence, the overall effect of kynurenine and AhR complex is shifting from osteogenic to adipogenic differentiation in BMSCs. CXCL12 acts via a feedback
regulation mechanism to downregulate IDO1 and AhR mRNA levels, while miR-29b-1-5p upregulates AhR mRNA level.
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reported in mice that received a high KYN diet (Refaey et al., 2017).
We believe that the effects of KYN reported here are primarily, but
not necessarily exclusively, mediated through AhR mediated signaling.
In other work, it was demonstrated that AhR activation can affect bone
health through downstream effects including reduced ossification as
well as inhibition of osteogenic differentiation and osteoblast functions
(Yun et al., 2018; Jamsa et al., 2001; Milbrath et al., 2009). Here, we
found that the use of the AhR antagonists DMF and CH-223192 in
combination with KYN partially rescued CXCL12 gene and protein ex-
pression. The anti-osteogenic action of KYN may be mediated through
other pathways as well. Indeed, it was recently reported that KYN can
regulate Wnt signaling and inhibit β-catenin expression, which is a key
regulatory pathway for osteogenesis and bone formation (Park et al.,
2018), and miR-29b-1-5p is predicted to potentially target Wnt1. Fur-
thermore, the miR-29b-1-5p mimic significantly upregulated AhR
mRNA expression levels, while both the miR-29b-1-5p inhibitor and
CXCL12 significantly downregulated those levels and CXCL12 also
downregulated IDO-1 expression. This result suggests that either miR-
29b-1-5p is upstream of AhR activation, or a feedback regulation me-
chanism exists between the two, as well as cross-talk between CXCL12
with IDO-1 and AhR, as well as being potentially able to target multiple
osteogenic genes. (Fig. 7).
In summary, we show that KYN contributes to bone aging via AhR
activation, which leads to upregulation of miR-29b-1-5p with down-
regulation of both Hdac3 and CXCL12. These combined effects lead to a
reduced osteogenic differentiation capacity in BMSCs, and contributes
to the aging-induced decline in bone formation. Whether the effects of
KYN are solely mediated via AhR is yet to be determined. We believe
that KYN pathway mediators including IDO-1 and AhR, as well as the
downstream molecules investigated in this work (CXCL12, Hdac3, and
miR29b-1-5p), offer new potential targets for clinical intervention to
prevent or treat osteoporosis.
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